New Rangeland Restoration Tool Effectively Controls Honey Mesquite and Huisache |
Invora™ Herbicide Receives EPA Federal ApprovalThis item has been supplied by a forage marketer and has not been edited, verified or endorsed by Hay & Forage Grower.The Vegetation Management business within Bayer CropScience LP, announces the label for its latest product. Invora™ Herbicide has received federal approval from the U.S. Environmental Protection Agency (EPA). The herbicide is federally registered for use on privately-owned, non-hayed rangeland and non-hayed perennial grasslands managed as rangeland in the states of Arizona, New Mexico, Oklahoma and Texas. Invora herbicide provides the following key benefits:
“We are so pleased to see Invora herbicide receive federal approval from the EPA,” said Bayer Head of Vegetation Management Marketing, North America, Tiffany Fremder. “It is truly exciting to provide ranchers with an innovative brush solution for their rangeland restoration needs by reducing the negative impacts of difficult-to-control brush, such as mesquite and huisache. The power to reclaim the land is now in their hands.” When considering the use of Invora herbicide, the following criteria must be followed:
First sales of Invora herbicide are anticipated in April 2020 following state registrations. For more information on Invora Herbicide, contact your local Bayer sales representative or visit: www.invora.com. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.us. |